21

KeyMed Biosciences IncHKG 2162 Stock Report

Last reporting period 30 Jun, 2022

Updated 19 Sep, 2024

Last price

Market cap $B

1.333

Small

Exchange

XHKG - Hong Kong Exchange

View Section: Price ratios

KeyMed Statements

21

KeyMed Income Statement

B

M

CNY (except Earnings per share)

Financial

Revenue

Cost of sales

Gross profit

Research and development

Selling, general and administrative

Total operating expenses

Operating income

Interest expense

Other income

Income before tax

Provision for income taxes

Net income

Diluted earnings per share

Shares outstanding after dilution

2022-06-30
%

100

100

2.537

2.5

97.463

97.5

164.01

164

51.048

51

201.75

201.8

-104.29

-104.3

106.82

106.8

0

2.524

2.5

0

5.454

5.5

0.02

267.34

2021-12-31
%

110.27

100

17.2

15.6

93.069

84.4

167.09

151.5

65.618

59.5

355.86

322.7

-262.79

-238.3

-10.729

-9.7

0

-262.2

-237.8

0

-258.81

-234.7

-5.104

50.702

2021-06-30
%

100

0

0

191.06

0

26.836

0

3 608.57

0

-3 608.57

0

5.89

0

0

-3 630.43

0

0

-3 628.5

0

-13.389

271

View Section: Balance Sheet